Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Share Price Shanghai S.E.

Equities

600332

CNE000001733

Pharmaceuticals

End-of-day quote Shanghai S.E. 23:00:00 28/04/2024 BST 5-day change 1st Jan Change
31.82 CNY +2.12% Intraday chart for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited +0.86% +11.26%

Financials

Sales 2024 * 80.8B 11.16B 889B Sales 2025 * 85.61B 11.82B 942B Capitalization 49.03B 6.77B 540B
Net income 2024 * 4.17B 576M 45.95B Net income 2025 * 4.44B 613M 48.83B EV / Sales 2024 * 0.37 x
Net cash position 2024 * 19.18B 2.65B 211B Net cash position 2025 * 22.46B 3.1B 247B EV / Sales 2025 * 0.31 x
P/E ratio 2024 *
7.83 x
P/E ratio 2025 *
7.54 x
Employees 28,048
Yield 2024 *
4.12%
Yield 2025 *
4.37%
Free-Float 49.33%
More Fundamentals * Assessed data
Dynamic Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Baiyunshan Pharmaceutical's 2023 Profit Rises 2% MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Announces Final Ordinary Dividend for the Year Ended 31 December 2023 CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Baiyunshan Pharma's Unit Gets Green Light to Produce Hepatitis B Drug MT
Guangzhou Pharma Unit Gets Green Light to Trial Oral Liquid Drug MT
Guangzhou Baiyunshan Pharmaceutical Arm Floats 1 Billion Yuan Biomedical VC Fund MT
Guangzhou Baiyunshan Pharmaceutical Ends Spin-Off Plans, Seeks China Listing for Subsidiary MT
Guangzhou Pharma Expands Scope of Drug Production License MT
Guangzhou Baiyunshan Pharmaceutical's Profit Up 11% in Q3 MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Baiyunshan Pharmaceutical Reports Increase in H1 Attributable Profit MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(SHSE:600332) added to Shanghai Stock Exchange 180 Value Index CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(SHSE:600332) added to SSE 180 Index CI
More news
1 day+2.12%
1 week+0.86%
Current month+10.29%
1 month+10.29%
3 months+11.65%
6 months+8.16%
Current year+11.26%
More quotes
1 week
30.92
Extreme 30.92
32.15
1 month
28.53
Extreme 28.53
32.45
Current year
26.50
Extreme 26.5
32.45
1 year
26.50
Extreme 26.5
37.09
3 years
25.32
Extreme 25.32
37.20
5 years
25.32
Extreme 25.32
44.94
10 years
19.60
Extreme 19.6
48.46
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 22/06/17
Chairman 57 -
Director/Board Member 47 31/12/14
Members of the board TitleAgeSince
Director/Board Member 76 27/06/10
Chairman 58 27/06/10
Director/Board Member 58 27/06/10
More insiders
Date Price Change Volume
29/04/24 31.82 +2.12% 13,597,050
26/04/24 31.16 -0.29% 8,423,401
25/04/24 31.25 -0.22% 6,218,615
24/04/24 31.32 -0.13% 7,565,233
23/04/24 31.36 -0.60% 9,698,877

End-of-day quote Shanghai S.E., April 28, 2024

More quotes
Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd. specializes in researching, developing and manufacturing pharmaceutical products. The group's products include analgesics, antibiotics, medicines for the treatment of stomach disorders, treatment of cough, antitoxic products, etc.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
19.52 CNY
Average target price
22.06 CNY
Spread / Average Target
+13.04%
Consensus

Quarterly revenue - Rate of surprise